Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

Go back to Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
(NASDAQ: XENE) Delayed: 35.44 -1.06 (2.9%)
Previous Close $36.50    52 Week High $9.75 
Open $36.62    52 Week Low $5.65 
Day High $36.62    P/E N/A 
Day Low $35.28    EPS $0.00 
Volume 298,593